Oruka Therapeutics (ORKA) Total Liabilities (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Total Liabilities of $17.8 million for Q1 2026, up 43.38% year-over-year from $12.4 million in Q1 2025, and up 6.43% quarter-over-quarter from $16.7 million in Q4 2025.
Oruka Therapeutics (ORKA) Total Liabilities (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $17.8 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 43.38% year-over-year to $17.8 million; the TTM figure through Mar 2026 stood at $17.8 million (up 43.38% YoY), while the FY2025 annual figure was $16.7 million, up 20.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $17.8 million, up from $16.7 million in the prior quarter.
- The five-year high for Total Liabilities was $22.5 million in Q3 2025, with the low at $841000.0 in Q4 2023.
- The 5-year median for Total Liabilities is $3.1 million (2022), against an average of $7.9 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities tumbled 63.62% in 2022, then soared 1540.67% in 2024.
- Oruka Therapeutics' Total Liabilities stood at $1.4 million in 2022, then tumbled by 40.44% to $841000.0 in 2023, then jumped by 1540.67% to $13.8 million in 2024, then grew by 20.94% to $16.7 million in 2025, then gained by 6.43% to $17.8 million in 2026.
- Business Quant data shows ORKA's Total Liabilities at $17.8 million in Q1 2026, $16.7 million in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 24.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.85 Mn |
| Mar 31, 2026 | 17.76 Mn |
| Dec 31, 2025 | 16.69 Mn |
| Sep 30, 2025 | 22.46 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Dec 31, 2024 | 13.80 Mn |
| Sep 30, 2024 | 18.88 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 841,000.00 |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 1.53 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Sep 30, 2021 | 3.59 Mn |